FLAGSTAFF, Ariz., June 13, 2017 — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that in an effort to ensure that the Company can meet the rapidly increasing demand for their innovative new rodent control technology, ContraPest, it has launched its second manufacturing line in Flagstaff. With the addition of this second line, the Company’s existing manufacturing capacity is expected to more than double.
Author Archive: AZBio
C-PATH and CDISC Announce Public Review Period for Duchenne Therapeutic Area Standard
The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the availability of a Duchenne muscular dystrophy therapeutic area user guide (TAUG-DMD v1.0) for public review. The review period for the TAUG-DMD v1.0 began on May 8, 2017, and runs through July 6, 2017. Qualified researchers and clinicians are encouraged to review TAUG-DMD v1.0 and offer feedback.Continue reading
ASU engineer working to develop disposable point-of-care sensor
The project aims to develop a disposable, point-of-care biosensor for rapid diagnosis and health monitoring, supported by a four-year, $1.8 million Smart and Connected Health award from the National Science Foundation.Continue reading
VisionGate Hires Prominent Pathologist as Medical Director
Former Massachusetts General Hospital’s Dr. David Wilbur To Oversee VisionGate’s CLIA laboratory. VisionGate’s ground-breaking technology can help eradicate not only the world’s deadliest disease – lung cancer — but other cancers as well.
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
CPP-1X/sulindac aims to prevent disease progression
Brain State Technologies: Successful clinical trial shows reduction of insomnia symptoms
HIRREM neurotechnology better than placebo for insomnia, and improvement of autonomic cardiovascular regulation
UA Research Says H. Pylori Needs Much Closer Attention
If the bacterium involved in a host of digestive maladies isn’t eradicated after treatment, that could indicate a resistance to antibiotics — and that’s worrisome.Continue reading
Castle Biosciences Presents Three New Clinical Studies at ASCO
Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma | Prospective, multicenter study confirms prognostic accuracy and performance | Newly expanded cohort shows promise in prognosis of Stage III melanoma